SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates potential catalysts and discusses key resistance levels to watch. Optimism is fueled by speculation around a possible ETF and increased adoption, with many hoping to see it reach higher price targets. Some traders suggest a cup and handle formation may be developing.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses potential drivers such as institutional buying and treasury firms increasing their SOL holdings. Conversations highlight the potential for a breakout and continued momentum, with some anticipating new all-time highs. The focus is on Solana's potential as a leading platform, with community members closely watching for further developments.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is gaining attention as the community speculates on potential catalysts and possible upward movement, with some expressing anticipation for significant gains. Community members are actively discussing holding strategies and debating the token's future prospects within the broader meme coin landscape. Despite mixed sentiment, optimism persists among some holders regarding SHIB's long-term potential.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community anticipates potential ETF approvals and discusses technical indicators suggesting a possible breakout. Community members are debating potential price movements, with some expressing excitement about potential gains, while others remain cautious. Discussions include the potential impact of regulation and real-world asset tokenization on XRP's future.

Ainalyzr is a versatile and engaging platform designed to provide crypto traders with advanced tools and a fun, interactive environment. Powered by the Ainalyzr token, it offers real-time analysis of Solana-based tokens, gamified trading tools, and a space for users to explore market trends and make data-driven decisions. Ainalyzr merges functionality and entertainment, appealing to both seasoned and novice traders.

AInalyzr

AInalyzr ($AINAL.X) is gaining attention, with community members highlighting its potential for a breakout and comparing it to early investments in established cryptocurrencies. Talk centers on the token's chart patterns, suggesting a possible surge, and the opportunity for early investors to benefit. The crypto is being touted as the next big play, urging others to stack now before it takes off.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amidst heated debates and political division following the tragic death of Charlie Kirk, with community members expressing strong opinions and accusations across the political spectrum. The catalyst seems to be the suspect's background and motivations, sparking intense speculation and finger-pointing. This occurs within a broader context of civil unrest rhetoric and concerns about the upcoming elections.

Trump For President

$TRUMP.X is trending amidst discussions about its potential and association with Donald Trump, with some traders weighing in on technical analysis and potential price movements. Conversations also involve heated political debates and comparisons to other meme coins. Some users reference an ETF filing, while others discuss the coin's performance relative to Bitcoin and other cryptocurrencies.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation of a potential acquisition by Paramount Skydance, driving significant market activity. Community discussions revolve around the strategic implications of the merger, potential bidding wars with other media giants, and speculation around the final buyout price. Investors are weighing potential synergies and regulatory hurdles in the ever-consolidating media landscape.

Moo Deng

Moo Deng is seeing increased chatter as the community discusses recent price movement and potential for further gains. Some traders are pointing to bullish setups and comparing it to similar meme coins, while others express concerns about previous pumps and dumps. Overall, the coin's potential within the meme coin sector is a key talking point.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is trending as community members discuss its potential as the next billion-dollar meme coin, highlighting its launch on Pump.fun and anticipating a significant price surge. Community members are also comparing it to other meme coins and touting its potential for high returns, while others suggest it may be overvalued. The coin's association with memetic culture and humorous branding contributes to its speculative appeal.

statis crypto Watchlist

Bitcoin

Ethereum

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Paris, France-based Abivax SA (ABVX) spiked by over 400% in Wednesday's early premarket session following a positive late-stage readout from the clinical-stage biotech.On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/ABVX">Abivax stock</a> improved further into the ‘extremely bullish’ territory (98/100), with the message volume score spiking to a near-perfect “99,” suggesting ‘extremely high’ retail chatter.<figure class="image"><img style="aspect-ratio:626/56;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_23_at_4_32_00_AM_png_77d276515d.webp" alt="Screenshot 2025-07-23 at 4.32.00 AM.png" width="626" height="56"><figcaption>ABVX sentiment and message volume as of 4:30 a.m., July 23 | source: Stocktwits</figcaption></figure>The Abivax stock stream on the platform saw a nearly 260% increase in watcher count over the 24 hours leading up to late Tuesday. The 24-hour message volume change was 3,900%.The stock was among the top five trending tickers on Stocktwits early Wednesday.The frenzied retail activity followed the small-cap biotech's announcement of positive topline results from two Phase 3 studies evaluating its obefazimod in adult patients with moderately to severely active ulcerative colitis (UC).Abivax evaluated a 50 mg once-daily oral dose of obefazimod, its lead candidate, in studies dubbed ABTECT 1 and ABTECT 2. The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study.It also met all key secondary endpoints, demonstrating “highly statistically significant and clinically meaningful benefits.”The company said an ABTECT Maintenance trial is ongoing, with topline results expected in the second quarter of 2026. It added that out of the 1,275 patients randomized in the induction trials, 678 achieved a clinical response and were enrolled in part 1 of the maintenance trial.Abivax CEO Marc de Garidel said, “The strength of these results reinforces our belief in obefazimod, our first-in-class miR-124 enhancer, and its potential to become a transformative new treatment modality for patients with UC.”Contingent upon the 44-week maintenance trial producing successful results, the company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.Abiva engages in the development of therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.A bullish Stocktwits watcher flagged a potential move toward the $60-$80 level on Wednesday.<stembedurl>https://stocktwits.com/europetradefuture/message/622045234</stembedurl>Another user, who identified themselves as a UC patient, said, “The addressable market is huge and physicians are always looking for another treatment option aside from TNFs, JAKs, interleukins, etc — some of the biggest blockbuster drugs currently treat UC/Crohns.”<stembedurl>https://stocktwits.com/Jblack500/message/622027325</stembedurl>Abivax stock is up over 36.5% for the year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/south-korean-feels-the-heat-after-japan-inks-trump-trade-deal-officials-in-dc/ch8wK2GR5M7">South Korea Feels The Heat After Japan Inks Trump Trade Deal — Officials In DC To Salvage Terms Before August Deadline</a>

Artwork based on an endoscopic image of the colon affected by ulcerative colitis (Photo Courtesy of Juan Gartner via Getty Images)

Small-Cap Abivax Spikes 400% On Positive Late-Stage Ulcerative Colitis Drug Trial Results  — Retail Buzz Builds Around Blockbuster Potential

The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study.

Equity

US-listed Abivax shares skyrocket on positive phase 3 data for colitis drug

Investing.com-- U.S.-listed shares of French biotech firm  Abivax SA  (EPA:ABVX) (NASDAQ:ABVX) skyrocketed in post-market trading on Tuesday after the company reported strong results from late-stage trials of its oral ulcerative colitis treatment, obefazimod.

Kepler Capital  Reaffirms Their Buy Rating on Abivax SA (0RA9)

In a report released on July 16, Justine Telliez from Kepler Capital maintained a Buy rating on Abivax SA (0RA9 Research Report), with a price ta...

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST Abivax SA (Euronext Paris & Nasdaq: ABVX) ( Abivax or the...

Abivax reports 2023 financial results and operational update

Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR...

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ('Abivax' or the 'Company'), a clinical-stage biotechnology company focused on developing therapeutics...

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET Abivax SA (Euronext Paris and Nasdaq: ABVX) ( Abivax or the Company ), a...

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease Obefazimod Crohn's Disease (CD) IND filed with the FDA in December...

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024...

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

ABVX
Abivax - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABVX News

ABVX Abivax - ADR